The Biden administration announced this morning it is rescinding the Trump administration’s regulatory requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income patients with high-cost or no health insurance.
The Biden administration this morning, as widely expected, announced it is rescinding the Trump administration’s regulatory requirement that community health [...] …
PhRMA recently urged CMS to establish a neutral clearinghouse and require accurate use of 340B claim modifiers to address nonduplication in its final guidance for Medicare drug price negotiations under the IRA.
Pharmaceutical Research and Manufacturers of America (PhRMA) asked a federal district court yesterday to rule that Arkansas’s 340B nondiscrimination act [...] …
A recent U.S. Supreme Court ruling confirms that the 340B administrative dispute resolution process is constitutional, government lawyers told a federal district judge this month.
A recent U.S. Supreme Court ruling about administrative law judges who hear patent disputes confirms that rules establishing the 340B [...] …
A federal district judge this week let six hospitals groups and a drug industry vendor file amicus briefs in Sanofi's 340B contract pharmacy lawsuit.
A federal district judge this week gave six hospital groups and a drug industry services provider permission to separately offer [...] …
It appears increasingly likely that congressional Democrats will miss their self-appointed deadline to pass and sent to President Biden this [...] …
Sen. John Kennedy (R-La.) has introduced legislation to preserve the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income, uninsured, and/or underinsured patients.
A Republican U.S. senator on an important health care spending committee wants Congress to pass a law preserving the Trump [...] …
Hospital groups urged congressional leaders in a Sept. 24 letter to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.
Six national hospital groups late last week urged Democratic and Republican congressional leaders to exclude language “that would negatively impact [...] …
Janssen Pharmaceuticals is providing refunds for 340B overcharges on 14 widely used products during the first and second quarters of 2021.
Drug manufacturer Janssen, a Johnson & Johnson company, has notified 340B covered entities they are or might be owed refunds [...] …
Sen. Chuck Grassley (R-Iowa), one of the most-engaged members of Congress on 340B matters, is seeking an eighth Senate term.
U.S. Sen. Chuck Grassley (R-Iowa)—one of the most-engaged members of Congress on 340B matters—has announced he will seek an eighth [...] …
A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs. …
*Sign up for news summaries and alerts from 340B Report
Copyright © 2025 340B Report, LLC
Reproduction of material from any 340B Report page without written permission is strictly prohibited.
